-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sorrento Therapeutics (NASDAQ:SRNE) Shares Down 9.5%
Sorrento Therapeutics (NASDAQ:SRNE) Shares Down 9.5%
Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating)'s share price traded down 9.5% on Thursday . The company traded as low as $1.53 and last traded at $1.53. 85,416 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 7,711,165 shares. The stock had previously closed at $1.69.
Sorrento Therapeutics Stock Down 6.5 %
The company has a quick ratio of 1.21, a current ratio of 1.35 and a debt-to-equity ratio of 0.61. The business's fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.05.
Get Sorrento Therapeutics alerts:Insider Buying and Selling at Sorrento Therapeutics
In related news, insider Henry Ji purchased 22,222 shares of Sorrento Therapeutics stock in a transaction on Thursday, August 25th. The stock was purchased at an average cost of $2.06 per share, with a total value of $45,777.32. Following the acquisition, the insider now directly owns 2,088,029 shares in the company, valued at $4,301,339.74. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.30% of the company's stock.
Hedge Funds Weigh In On Sorrento Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in SRNE. BNP Paribas Arbitrage SA lifted its holdings in shares of Sorrento Therapeutics by 27.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 64,093 shares of the biopharmaceutical company's stock worth $298,000 after acquiring an additional 13,817 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Sorrento Therapeutics by 26.9% during the 4th quarter. Teacher Retirement System of Texas now owns 54,438 shares of the biopharmaceutical company's stock worth $253,000 after acquiring an additional 11,530 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Sorrento Therapeutics during the 4th quarter worth about $115,000. JPMorgan Chase & Co. lifted its holdings in shares of Sorrento Therapeutics by 21.8% during the 4th quarter. JPMorgan Chase & Co. now owns 3,574,317 shares of the biopharmaceutical company's stock worth $16,621,000 after acquiring an additional 639,306 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Sorrento Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 304,405 shares of the biopharmaceutical company's stock worth $1,415,000 after acquiring an additional 5,653 shares during the period. 33.61% of the stock is owned by institutional investors.About Sorrento Therapeutics
(Get Rating)
Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Recommended Stories
- Get a free copy of the StockNews.com research report on Sorrento Therapeutics (SRNE)
- What Cintas Can Teach Investors About This Bear Market?
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- A Trio of Q3 Winners With Room to Run
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
索伦托治疗公司(纳斯达克代码:SRNE-GET)股价周四下跌9.5%,盘中最低跌至1.53美元,尾盘报1.53美元。午盘,85,416股股票易手,较7,711,165股的平均成交量下跌99%。该股此前收盘报1.69美元。
索伦托治疗公司股价下跌6.5%
该公司的速动比率为1.21,流动比率为1.35,债务权益比为0.61。该业务的50日简单移动均线切入位为2.21美元,200日简单移动均线切入位为2.05美元。
到达索伦托治疗公司警报:索伦托治疗公司的内幕买卖
相关新闻,内部人士纪万昌在8月25日(星期四)的一笔交易中购买了22,222股索伦托治疗公司的股票。这只股票是以每股2.06美元的平均成本购买的,总价值为45,777.32美元。收购完成后,这位内部人士现在直接持有该公司2,088,029股股票,价值4,301,339.74美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在这个环节。内部人士持有该公司3.30%的股份。
对冲基金入股索伦托治疗公司
一些对冲基金和其他机构投资者最近改变了他们在SRNE的头寸。法国巴黎银行套利公司在第四季度增持了索伦托治疗公司的股票27.5%。法国巴黎银行套利公司现在持有这家生物制药公司64,093股股票,价值29.8万美元,在此期间又购买了13,817股。德克萨斯州教师退休系统在第四季度增持了索伦托治疗公司的股票26.9%。德克萨斯州的教师退休系统现在拥有这家生物制药公司54,438股股票,价值253,000美元,在此期间又购买了11,530股。Qube Research&Technologies Ltd在第四季度购买了索伦托治疗公司的新股票头寸,价值约11.5万美元。摩根大通在第四季度增持了索伦托治疗公司的股票21.8%。摩根大通在此期间增持了639,306股,目前持有这家生物制药公司3,574,317股股票,价值16,621,000美元。最后,Rhumbline Advisers在第四季度将其在Sorrento Treeutics的股票持有量增加了1.9%。在此期间,Rhumbline Advisers额外收购了5653股,现在拥有304,405股这家生物制药公司的股票,价值1,415,000美元。33.61%的股份由机构投资者持有。关于索伦托治疗公司
(获取评级)
索伦托治疗公司是一家临床阶段和商业生物制药公司,开发癌症、自身免疫、炎症、病毒和神经退行性疾病的治疗方法。它通过两个部门运营,索伦托治疗公司和Scilex。该公司通过利用其专有的G-MAB抗体库和靶向递送方式提供癌症治疗,其中包括嵌合抗原受体T细胞疗法(CAR-T)、二聚体抗原受体T细胞疗法、抗体药物结合物以及双特异性抗体方法;以及Sofusa,一种将生物细胞直接输送到淋巴系统的药物递送技术。
推荐故事
- 免费获取StockNews.com关于索伦托治疗公司(SRNE)的研究报告
- 关于这个熊市,Cintas能教给投资者什么?
- 这家小盘股医疗保健公司的表现好于其指数
- 值得一看的2只赌场股票
- 黑莓股价下跌,业绩再次不温不火
- 第三季度赢家三人组还有运行的空间
接受《索伦托治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对索伦托治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧